Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02581930 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT02581930 · ClinicalTrials.gov record · last posted 2026-08-11

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

StatusCompleted
PhasePhase 2
Started2016-12-16
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This phase II trial studies how well ibrutinib works in treating patients with stage IV melanoma of the skin that has not responded to previous treatment. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Protocol amendment history 3 changes detected by DataLookout

2026-08-12
Trial completed
2026-08-12
Primary completion pushed: 2018-02-10 → 2021-09-09
2026-08-12
Completion moved earlier: 2027-03-04 → 2021-09-09
Trial Details
NCT Number NCT02581930
Lead Sponsor National Cancer Institute (NCI)
Conditions Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
Enrollment 18 participants
Start Date 2016-12-16
Primary Completion 2021-09-09 (estimated)
Study Completion 2021-09-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-11